Overview

Single-Dose Study of MT203

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate safety, pharmacokinetics and pharmacodynamics of single subcutaneous injection of MT203 in healthy adult Japanese and Caucasian male participants.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Antibodies, Monoclonal